Search

everythinglearnresearchcommunity

for

Search:↓

User had a 5000-hair FUT procedure in South Korea in 2014 and is satisfied with results. Uses Minoxidil, dermarolling, and Toppik hair fibers for crown area, and considering Finasteride.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation discusses the appearance of hair transplants immediately after surgery, noting that scars will be covered as hair grows. The original poster underwent both FUT and FUE procedures.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.

User shared 1-year progress of hair growth using Fin, Min, Micro, Alfatradiol, and vitamins. Photos show improved hairline and increased grays.

A 48-year-old man has been using finasteride at 1mg three times a week for two years, seeing some hair regrowth but noting lighting affects appearance. He is considering adding minoxidil but is concerned about shedding.

The conversation discusses the fluctuation of testosterone levels in men under 40 and the difference between serum DHT and scalp DHT. It also mentions that DHT levels are higher on Dutasteride than on Finasteride, which is unusual.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.

A 42-year-old shares progress using finasteride and dutasteride for 9 months, with occasional minoxidil use, noticing results after a month. The user applied minoxidil consistently for 3 months, then sporadically once a week.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

The conversation is about a user who got a perm after successfully treating their thinning hair, with mixed reactions from others on the appearance. Specific treatments used are not mentioned.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.

The conversation is about obtaining alfatradiol in Canada, specifically in Quebec, and whether it requires a prescription or can be bought online. A user suggests ordering it from a specific website.

A satirical post jokes about a user meeting a doctor at the zoo who praises finasteride (Fin) for hair loss treatment, claiming it has a low side-effect profile and is effective. Replies include humorous disbelief, comparisons to other risks, and some personal accounts of side effects from Fin.

A 24-year-old had an FUE hair transplant in Liverpool at age 23, after starting finasteride at 20 to halt hair loss. The transplant involved 3000 grafts, and the user is satisfied with the results, noting increased confidence and no further hairline recession.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

User shared 1-year progress on Fin 1 mg, switching to 0.4 mg Dut and oral 1.25 mg Min. Good results with Fin, biotin supplement, and biotin shampoo; trying Dut and oral Min for potential better results.

The user plans to use a "nuclear protocol" for hair improvement, including topical minoxidil 12.5%, topical finasteride 0.1%, and tretinoin 0.05%, with microneedling once a week. They have seen improvements with minoxidil and are seeking opinions on their approach to achieve thicker hair.